Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 17/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384493 | 0.86 | PDE10A (0.71) | PDE10A | |
| SCHEMBL2384309 | 0.85 | PDE10A (0.64) | PDE10A | |
| SCHEMBL6915916 | 0.84 | PDE10A (0.76) | PDE10A | |
| SCHEMBL12316438 | 0.83 | PDE10A (0.74) | PDE10A | |
| SCHEMBL2385693 | 0.83 | PDE10A (0.61) | PDE10A | |
| SCHEMBL2400200 | 0.83 | PDE10A (0.67) | PDE10A | |
| SCHEMBL2372512 | 0.83 | PDE10A (0.71) | PDE10A | |
| SCHEMBL12266633 | 0.83 | PDE10A (0.74) | PDE10A | |
| SCHEMBL2396915 | 0.83 | PDE10A (0.64) | PDE10A | |
| SCHEMBL2401858 | 0.83 | PDE10A (0.64) | PDE10AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552918-B1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | claimed |
| US-8410117-B2 | Imidazopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | claimed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | claimed |
| EP-2552918-B1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | disclosed |
| US-8410117-B2 | Imidazopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410117-B2 | Imidazopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | PDE5A, PDE3B, PDE3A | PDE10A 10/4885MEN1 3260/4885LMNA 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.